LNTH:NSD-Lantheus Holdings Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 93.82

Change

+2.61 (+2.86)%

Market Cap

USD 0.33B

Volume

0.84M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lantheus Holdings Inc is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products. These products assist clinicians in the diagnosis of cardiovascular and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

+0.05 (+0.42%)

USD 15.08B
NBIX Neurocrine Biosciences Inc

+0.70 (+0.51%)

USD 13.98B
ITCI Intracellular Th

+1.45 (+1.77%)

USD 8.88B
ALKS Alkermes Plc

+0.07 (+0.25%)

USD 4.70B
ALVO Alvotech

-0.20 (-1.50%)

USD 4.00B
HCM HUTCHMED DRC

-0.64 (-4.05%)

USD 2.64B
SUPN Supernus Pharmaceuticals Inc

+0.38 (+1.03%)

USD 2.05B
AMPH Amphastar P

-0.18 (-0.51%)

USD 1.75B
DVAX Dynavax Technologies Corporati..

+0.07 (+0.55%)

USD 1.71B
EVO Evotec SE ADR

+0.15 (+3.38%)

USD 1.70B

ETFs Containing LNTH

W311:F HAN-GINS Indxx Healthcare.. 4.62 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 4.62 % 0.00 %

+0.01 (+-0.28%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.62 % 0.00 %

+0.01 (+-0.28%)

N/A
MEDI Harbor Health Care ETF 3.31 % 0.00 %

-0.07 (-0.28%)

USD 0.02B
GRPM Invesco S&P MidCap 400 GA.. 3.01 % 0.00 %

-0.32 (-0.28%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.39 % 0.00 %

+0.40 (+-0.28%)

N/A
QWST 1.37 % 0.00 %

N/A

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.58 % 0.00 %

-1.39 (-0.28%)

USD 0.23B
RTWP:LSE Legal & General UCITS ETF.. 0.58 % 0.00 %

-96.50 (-0.28%)

USD 0.23B
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

-2.15 (-0.28%)

N/A
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

-0.44 (-0.28%)

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

-3.26 (-0.28%)

USD 1.19B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

-0.88 (-0.28%)

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.01 (-0.28%)

N/A
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

-1.42 (-0.28%)

USD 0.09B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.87% 60% D- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.87% 60% D- 69% C-
Trailing 12 Months  
Capital Gain 43.68% 90% A- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.68% 90% A- 84% B
Trailing 5 Years  
Capital Gain 367.93% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 367.93% 96% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 68.28% 87% B+ 90% A-
Dividend Return 68.28% 87% B+ 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.95% 51% F 30% F
Risk Adjusted Return 101.98% 99% N/A 97% N/A
Market Capitalization 0.33B 96% N/A 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.70 57% 57%
Price/Book Ratio 5.43 25% 23%
Price / Cash Flow Ratio 20.97 14% 15%
Price/Free Cash Flow Ratio 9.44 34% 37%
Management Effectiveness  
Return on Equity 45.53% 99% 97%
Return on Invested Capital 23.52% 93% 90%
Return on Assets 17.00% 99% 99%
Debt to Equity Ratio 68.84% 22% 33%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.